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Abstract Background Homocysteine levels in circulation
are determined by several factors and hyperhomocystein-
emia is reportedly associated with cardiovascular diseases
and dementia. The aim of this study is to determine the
relation of chronic gastritis and other conditions to homo-
cysteine levels and their relation to incident cardiovascular
diseases and dementia. Methods An adult population-based
cohort (N = 488) was screened for H. pylori infection,
gastro-duodenitis (endoscopic biopsies), disease history,
and lifestyle factors. Blood samples were analyzed for
pepsinogen I and II (gastric function), vitamin B12, folate,
homocysteine, and cystatin C (renal function). The meth-
ylenetetrahydrofolate reductase C677T polymorphism
reportedly associated with hyperhomocysteinemia was
analyzed by pyrosequencing. Incident cardiovascular dis-
eases and dementia were monitored during a median
follow-up interval of 10 years. Results At baseline, there
was a positive relation of S-homocysteine to male gender,
age, S-cystatin C, methylenetetrahydrofolate reductase
677TT genotype and atrophic gastritis. During follow-up,
cardiovascular diseases occurred in 101/438 and dementia
in 25/488 participants, respectively. Logistic regression
analysis (adjusting for gender, age at baseline, follow-up
interval, BMI, smoking, alcohol consumption, NSAID use,
P-cholesterol, and P-triglycerides) showed an association
of S-homocysteine higher than 14.5 lmol/l to cardiovas-
cular diseases (OR 2.05 [95% c.i. 1.14–3.70]), but not to
dementia overall. Conclusions Gender, age, vitamin B12,
folate, renal function, atrophic gastritis and the methyl-
enetetrahydrofolate 677TT genotype were signiﬁcant
determinants of homocysteine levels, which were posi-
tively related to incident cardiovascular diseases.
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Introduction
Homocysteine (Hcy) metabolism is dependent on several
factors, such as S-adenosylmethionine (SAM), vitamin B12
as a cofactor, and methyltetrahydrofolate as the substrate.
Deﬁciency of these or of other substances, as well as
enzymatic defects, disturb the metabolism and may lead
to hyperhomocysteinemia [1]. Methylenetetrahydrofolate
reductase (MTHFR) catalyzes the reduction of 5,
10-methylenetetrahydrofolate to 5-methyltetrahydrofolate,
acting as methyl donor in the conversion of Hcy to
methionine [1]. The MTHFR single nucleotide polymor-
phism (SNP) C677T (SNPdb ID: rs1801133) is known to
yield an enzyme with reduced activity, which leads to mild
hyperhomocysteimia [2].
Hyperhomocysteinemia may cause damage to the intima
of the vascular wall [3]. It has been linked to cardio-
vascular diseases, dementia, diabetes mellitus (DM), hypo-
thyreosis, and renal disease [3–7]. The levels of Hcy in
circulation are inversely related to renal function [8]. The
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[9, 10] and dementia [11, 12] has been shown in several
studies, but is controversial [13, 14]. The cut-off value for
the Hcy concentration used to deﬁne hyperhomocystein-
emia is poorly deﬁned. Levels around 14–15 lmol/l have
been used [3, 5, 7, 10–12, 15].
Deﬁciencies of vitamin B12 and folate are common
etiologies of hyperhomocysteinemia. Untreated celiac dis-
ease is frequently associated with folate deﬁciency and, to
a lower rate, with vitamin B12 deﬁciency [16, 17]. A fre-
quent cause of vitamin B12 deﬁciency is atrophy of the
gastric corpus mucosa, which leads to reduced intrinsic
factor secretion, i.e., latent or overt pernicious anemia.
Helicobacter pylori (H. pylori) infection per se, irrespec-
tive of atrophy of the gastric mucosa, was found to be
associated with reduced vitamin B12 in circulation [18,
19]. However, a meta-analysis showed no association of
H. pylori infection to coronary heart disease [20].
The objective of this 10-year follow-up study of a
population-based cohort was to investigate what impact
H. pylori infection, chronic gastritis, MTHFR C677T SNP,
renal dysfunction, and some other conditions have on
variations in Hcy levels in circulation and, furthermore, to
explore the relations of Hcy levels to subsequent devel-
opment of cardiovascular diseases and dementia.
Methods
Study Population and Follow-Up
The study was performed in accordance with the Helsinki
Declaration and was approved by the local ethics com-
mittee. Informed written consent was obtained from all
participants.
The prevalence of gastritis, duodenitis, and H. pylori
infection in this cohort have been published [21, 22]. Five-
hundred-and-one randomly selected subjects (age 35–
85 years and equal number of women and men at selection)
in the general population underwent esophago–gastro-
duodenoscopy (EGD) with biopsy. A complete histomor-
phological examination of biopsies from both the gastric
corpus and antrum was obtained in 488 participants. These
488 participants make up the cohort studied here and which
comprises 225 women and 263 men with median ages of
62 (min 38-max 85) years and 60 (37–82) years, respec-
tively, at baseline. Histomorphological examination of
biopsies from the second part of the duodenum was
achieved in 474 participants.
At baseline, the participants received a self-administered
questionnaire exploring details about previous and cur-
rent diseases, body weight, and height, current smoking,
use of alcohol, and current medications including the use
of aspirin (including low-dose) or other potentially
ulcerogenic NSAIDs. Eight years (minimum) after base-
line, the same questionnaire was distributed. In addition,
in-hospital diagnoses recorded before and after baseline
including causes of death among deceased participants
were extracted from local patient ﬁles (including those of
the Memory Reception, Department of Geriatric Medicine)
as well as from the records of Statistics Sweden (SCB) and
the Swedish National Board of Health and Welfare.
Nationwide reporting to the latter goes back to 1964 (full
cover by 1987). Files were screened up to 2005.
In case of incident cardiovascular diseases, one diagnosis
was assigned to each participant. Myocardial infarction was
given the highest priority. The priority of other diagnoses in
descending order was: ischemic heart disease (angina pec-
toris), aortic or other arterial aneurysm, transient ischemic
attack (TIA) or stroke, and cardiac arrhythmia and/or heart
failure; all without a registered diagnosis of myocardial
infarction. Hypertension as the sole diagnosis was not
included since primarily this diagnosis is set in primary
health care, and is probably underreported and latent/sub-
clinical in the general population.
In the total cohort of 488 participants, 50 had a history of
a cardiovascular disease at baseline (myocardial infarction
ten, angina pectoris 17, TIA/stroke four, and cardiac
arrhythmia and/or heart failure 19). None had known
dementia, since that precluded participation. Ninety-nine of
485 responders were current smokers, 78 of 476 responders
used spirits and/or wine every week, and 81 of 476
responders used aspirin or other NSAID every week. There
were 438 participants (207 women and 231 men, age 59.4
(36.8–84.9) years) with no history of a cardiovascular dis-
ease or dementia at baseline (smokers 93 of 435 responders;
use of alcohol every week 71 of 429 responders; use of
aspirin or other NSAID every week 60 of 427 responders).
At baseline, 14 participants had DM (one type 1 and 13
type 2). During the follow-up period, four developed type 2
DM. Twenty-six participants had thyroid disease, classiﬁed
as hypothyroid disease in six. During follow-up, one par-
ticipant underwent surgery for non-speciﬁed thyroid
disease. Three participants had a history of renal disease
(one operated and one non-operated for cystic disease, and
one operated for renal carcinoma). During follow-up,
nephritis was diagnosed in one and renal carcinoma in two
participants.
Histological Examinations and H. pylori Status
Routinely prepared biopsy sections (three biopsies from the
corpus, antrum and second part of the duodenum) were
stained with hematoxylin-eosin, Alcian blue-periodic acid-
Schiff, and Giemsa stain as previously described [21].
Gastritis was classiﬁed according to the Sydney system,
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of H. pylori [23]. Considering glandular atrophy of the
gastric corpus mucosa, moderate to severe atrophy was
taken into account in the present study. Atrophy of the
duodenal mucosa was histologically classiﬁed according to
Alexander [24], and in the present study it was deﬁned as
grade III or grade IV.
An experienced pathologist (FP) who had no informa-
tion about other data performed the microscopic
examinations.
H. pylori status was classiﬁed as previously described,
i.e., positive if at least one of serology, histology and
urease-test on fresh biopsy specimens [21] indicated
infection. The study was non-interventional regarding
H. pylori infection. However, the infection was treated at
baseline in 15 participants who at screening were shown to
have H. pylori associated ulcer disease [21]. None of these
had atrophic gastritis.
Blood Analyses
At baseline, blood samples were collected in a fasting state
immediately preceding EGD. The samples were stored
at -80C. Sera were analyzed (Biohit Diagnostics,
Helsinki, Finland) for vitamin B12 (pmol/l), folate (nmol/l)
and Hcy (lmol/l) concentrations with the Immulite
 1000
method (DPC, Los Angeles, CA, USA) according to the
manufacturer’s instructions. Samples were run at the same
time to minimize assay variability. Pepsinogens in serum
were measured with a sandwich enzyme immunoassay
(ELISA) utilizing a pepsinogen I (PGI) and pepsinogen II
(PGII) speciﬁc capture antibody, respectively, and a
horseradish peroxidase (HRP) detection antibody (from
GastroPanel
, Biohit Diagnostics, Helsinki, Finland).
There is no cross reactivity between the two assays. The
reference interval is 30.0–120.0 lg/l for PGI, 3.0–10.0 lg/l
for PGII and 3.0–20.0 for the ratio PGI/PGII. Values of
PGI/PGII lower than 3.0 were considered as indicative of
signiﬁcant atrophy of the gastric corpus mucosa.
P-total cholesterol (mmol/l) and P-triglycerides (mmol/l)
were measured withthe Hitachi 717 (Boehringer Mannheim
Scandinavia AB, Stockholm, Sweden) using speciﬁc
reagent 1.
CystatinCinserumwasanalyzedwithAdvia1650(Bayer
AB, Gothenburg, Sweden) using reagent DakoCystatin C at
the Dept. of Clinical Chemistry, University Hospital,
Linko ¨ping, Sweden (reference interval for ages 1–50 years :
0.7–1.21 mg/l and for ages[50 years: 0.84–1.55 mg/l).
MTHFR SNP 677 Genotype Analysis
DNA from blood samples (whole blood, plasma, or serum)
was extracted, ampliﬁed and quality assessed as previously
described [25]. Primers for MTHFR C677T (rs1801133)
pyrosequencing analysis were designed based on the
available MTHFR genomic sequence (GenBank accession
number NT_021937, region: 6388104-6400540) using the
PSQ Assay design software (Biotage, Uppsala, Sweden).
The primers Biotin-MTHFR677.se (ccgaagcagggagctttga),
MTHFR677.as (caagtgatgcccatgtcg), and sequencing
primer Seq-MTHFR677 (cgtgatgatgaaatcg) were used.
PCR products were obtained using the HotStarTaq Plus
Mastermix kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions, using 5 pmol of each primer,
and the PCR program: 95C 5 min; 35 cycles of 95C3 0s ,
60C3 0s ,7 2 C 1 min; ﬁnal extension 72C 10 min. The
PCR products were analyzed by pyrosequencing as previ-
ously described [25].
Statistical Analyses
Numerical data were summarized as median (min–max)
unit. The Mann–Whitney U-test was used for comparisons
of continuous data between groups while Fisher’s exact test
was used for dichotomous data. Correlations were tested
with Spearman’s rank correlation test. A general linear
model (GLM) was used to identify factors with impact on
S-Hcy concentrations. Logistic regression analysis was
performed in which incident cardiovascular diseases
overall or dementia overall were included as the dependent
variable. Goodness-of-ﬁt was tested with the Hosmer–
Lemeshow’s method. Coefﬁcients in GLM and odds ratios
(OR) in logistic regression are given with [95% conﬁdence
intervals]. In every analysis, a two-sided P-value of\0.05
was regarded as signiﬁcant.
Results
At baseline, 246 participants had histologically normal
gastric mucosa with negative H. pylori status, 209 had
chronic gastritis with positive H. pylori status, and 33 had
chronic gastritis with negative H. pylori status. Atrophy of
the corpus mucosa was diagnosed histomorphologically in
21 of the 488 participants (15 with positive H. pylori sta-
tus). Twenty of 474 examined participants had a subnormal
PGI/PGII value (\3.0) and 28 of 475 participants had
atrophy either according to histological examination and/or
the PGI/PGII value. Villous atrophy of the duodenal
mucosa was diagnosed in nine participants. The distribu-
tion of the MTHFR 677 genotype among 483 successfully
analyzed participants was 50.1% CC, 38.5% TC, and
11.4% TT while an S-Cystatin C concentration above the
reference range was present in 18 of 473 participants
examined.
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(P\0.001) correlation between age and S-Hcy (rho =
0.26), age and S-cystatin C (rho = 0.40), S-Hcy and
S-cystatin C (rho = 0.22), S-vitamin B12 and S-Hcy
(rho =- 0.28) and S-folate and S-Hcy (rho =- 0.24).
S-Hcy concentrations were lower in women than in men
(12.0 (2.9–35.7) lmol/l vs 13.9 (5.8–50.0) lmol/l; 222
women and 257 men were examined; P\0.001) and S-
vitamin B12 concentrations were higher in women than in
men (288 (118–789) pmol/l vs. 259 (98–742) pmol/l; 208
women and 233 men were examined; P = 0.005). S-folate
and S-cystatin C concentrations did not differ between the
sexes.
S-Hcy concentrations were elevated in participants with
DM and in those with elevated S-cystatin C (Table 1).
Table 2 shows that S-Hcy concentrations were increased
among participants with atrophic gastritis, but not in those
with H. pylori-associated gastritis without atrophy. Con-
sidering participants with subnormal PGI/PGII, indicative
of atrophy of the gastric corpus mucosa, results were
similar with median S-Hcy 17.5 (9.8–50.0) lmol/l among
participants with subnormal PGI/PGII and 12.5 (2.9–
33.1) lmol/l among those with PGI/PGII within normal
range (P\0.001).
S-Hcy levels did not differ signiﬁcantly between
participants with the MTHFR 677 TT genotype (13.0
Table 1 S-Hcy concentrations in participants with condition reportedly associated with hyperhomocysteinemia
Condition present at baseline No. of participants
examined
P-homocysteine, lmol/l,
median (min–max)
P (Mann–Whitney U-test)
when compared to participants
with none of these conditions
Diabetes mellitus 13 15.4 (11.0–29.0) 0.01
Hypothyreosis 6 10.6 (9.6–14.4) 0.23
Renal dysfunction (S-cystatin
C above reference range)
a
17 16.4 (9.4–29.6) 0.01
MTHFR 677 TT genotype
a 51 13.0 (7.6–50.0) 0.13
None of these conditions 392 12.4 (2.9–48.3)
a In nine samples, Cystatin C or MTHFR 677 could not be determined
Table 2 S-vitamin B12, S-folate, and S-homocysteine concentrations in relation to histomorphology in the gastric and duodenal mucosa
at baseline
Gastro-duodenal histomorphology Vitamin B 12, pmol/l Folate, nmol/l Homocysteine, lmol/l
Median (min–max)
no. examined
P
Median (min–max)
no. examined
P
Median (min–max)
no. examined
P
Normal gastric mucosa without H.pylori infection 266 (118–663) 9.9 (2.1–35.2) 12.2 (2.9–33.1)
220 215 242
–– –
H. pylori-associated chronic gastritis
without signiﬁcant atrophy of the corpus
mucosa
282 (98–789) 9.0 (3.1–36.3) 13.1 (4.8–35.7)
179 175 190
0.72
a 0.21
a 0.06
a
Non-H. pylori-associated chronic gastritis
without signiﬁcant atrophy of the corpus
mucosa
281 (161–575) 12.1 (5.1–30.0) 12.0 (8.7–21.2)
27 24 27
0.86
a 0.08
a 0.50
a
Chronic gastritis with atrophy of the corpus
mucosa with or without H. pylori infection
269 (107–497) 9.6 (4.0–24.2) 20.1 (10.2–50.0)
15 19 20
0.14
a 0.61
a \0.001
a
No signiﬁcant villous atrophy
of the duodenal mucosa
269 (98–789) 9.6 (3.1–36.3) 12.7 (2.9–50.0)
430 422 467
–– –
Villous atrophy of the duodenal mucosa
(Alexander grade III to IV)
319 (224–603) 6.1 (2.1–12.8) 13.9 (8.5–33.1)
88 9
0.16
b 0.02
b 0.47
b
a P-value from the Mann–Whitney U-test when compared to participants with normal gastric mucosa
b P-value from the Mann–Whitney U-test when compared to participants with mild or no villous atrophy of the duodenal mucosa
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123(7.6–50.0) lmol/l) and those with the CT (12.7 (4.8–
33.1) lmol/l) or CC genotype (12.7 (2.9–48.3) lmol/l), nor
was there any relation between S-Hcy levels and the
presence of the T allele (12.8 (4.8–50.0) lmol/l).
GLM analysis (Table 3) showed that S-Hcy concentra-
tions were related to gender, age, S-cystatin C, S-vitamin
B12, S-folate, MTHFR 677 TT genotype, and the occur-
rence of atrophic gastritis. Substituting the morphological
diagnosis of atrophic gastritis in Table 3 for subnormal
PGI/PGII yielded similar results overall and the coefﬁcient
for subnormal PGI/PGII was 5.96 (95% c.i. 3.35–8.56,
P\0.001). When H. pylori-associated chronic gastritis
without signiﬁcant atrophy of the corpus mucosa was
included in the model, no signiﬁcant relation to S-Hcy was
shown.
At baseline, 438 participants had no history of any
cardiovascular disease. They were followed-up for 129 (9–
178) months (4,796 person years), during which 101 were
diagnosed with cardiovascular disease. These were myo-
cardial infarction [28], angina pectoris [17], abdominal
aortic aneurysm [6], TIA/stroke [18], and cardiac arrhyth-
mia/heart failure [32]. The median follow-up time for all
488 participants was 128 (1–180) months (5,262 person
years). Among all 488 participants, 25 developed dementia.
In six, the form of dementia was classiﬁed as Alzheimer’s
disease, in three as vascular dementia, in six as mixed
dementia, and in ten it was not classiﬁed. Mild cognitive
impairment (diagnosed in ﬁve participants) was not deﬁned
as dementia.
The prevalence of atrophic gastritis was 9/101 among
participants with incident cardiovascular diseases and 7/337
among participants not diagnosed with any cardiovascular
disease during follow-up (P = 0.004). Corresponding
ﬁgures for dementia were 3/25 and 18/463, respectively
(P = 0.09). The prevalence of positive H. pylori status did
not differ signiﬁcantly between participants with and with-
out incident cardiovascular diseases or dementia.
S-Hcy was found to be elevated among participants
developing cardiovascular diseases (14.4 (4.6–37.3) lmol/
l) compared to those without such diseases (12.1 (2.9–
48.3) lmol/l) (P = 0.001). S-Hcy levels in subgroups are
shown in Table 4.
The median for S-Hcy was 15.7 (11.2–28.4) lmol/l
among participants developing dementia and 12.7 (2.9–
Table 3 General linear model
estimates of factors with
putative impact on S-
homocysteine concentration
(dependent variable)
Independent variable Coefﬁcient 95% conﬁdence
interval (min–max)
P
Male gender 1.57 0.65–2.49 0.001
Age 0.08 0.0–0.13 0.001
BMI -0.03 -0.17–0.10 0.62
Diabetes mellitus 2.52 -0.42–5.46 0.09
Hypothyreosis 0.84 -2.92–4.60 0.66
S-cystatin C 2.71 1.26–4.15 \0.001
S-vitamin B12 -0.01 -0.01–0.00 \0.001
S-folate -0.16 -0.24–-0.08 \0.001
MTHFR 677 TT genotype 1.645 0.27–3.02 0.02
Atrophy of the gastric corpus mucosa 4.62 2.00–7.24 0.001
Atrophy of the duodenal mucosa
(Alexander grade III–IV)
2.50 -0.75–5.76 0.13
Table 4 S-homocysteine concentrations at baseline in participants diagnosed with cardiovascular diseases during follow-up
Diagnosis No. of participants
examined
S-homocysteine, lmol/l
median (min–max)
P-value
a when compared to participants
with no known cardiovascular disease
No known cardiovascular disease
(hypertension disregarded)
331 12.1 (2.9–48.3)
Myocardial infarction 26 15.1 (8.7–37.3) \0.001
Ischemic heart disease (angina pectoris) 17 13.0 (7.3–25.6) 0.24
Aortic Aneurysm 5 21.0 (10.7–24.2) 0.02
TIA or stroke 18 11.7 (4.6–35.7) 0.91
Cardiac failure and/or arrhythmia 32 13.2 (6.9–28.4) 0.15
a Mann–Whitney U-test
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12350.0) lmol/l among participants without dementia
(P = 0.004). With regard to the subgroups, S-Hcy was
20.0 (12.0–23.1) lmol/l in vascular dementia, 16.2 (12.2–
25.3) lmol/l in Alzheimer’s disease, 11.9 (11.2–12.5)
lmol/l in mixed dementia and 16.7 (12.2–28.4) lmol/l in
non-speciﬁed dementia. The difference of their S-Hcy
levels in relation to participants without dementia was
close to signiﬁcant for Alzheimer’s disease (P = 0.05) and
signiﬁcant for non-speciﬁed dementia (P = 0.004).
Table 5A shows the results of the logistic regression
analyses with cardiovascular diseases considered together
as the dependent variable and S-Hcy as a continuous or
dichotomous independent variable with different cut-off
levels. Exchanging S-Hcy in this model for gastric mucosal
atrophy (as determined morphologically or with PGI/PGII),
MTHFR 677 TT genotype and elevated cystatin C taken
together as an independent variable, showed no signiﬁcant
relation to cardiovascular diseases (OR 1.70 [0.92–3.13]
with morphological determination). As shown in Table 5B,
there was no signiﬁcant association between S-Hcy and
subgroups of dementia considered together.
Discussion
As is the case with most population-based cohorts, one may
question whether the present one is representative. The
incidence of myocardial infarction found was at approxi-
mately the same level as reported by the Swedish National
Board of Health and Welfare (www.socialstyrelsen.se).
Also, the incidence of dementia was at the same level as
previously reported in Sweden [26]. However, considering
the invasive character of the EGD, which the participants
were asked to undergo, the participation rate became rel-
atively low and there may have been a selection bias based
on the occurrence of digestive symptoms [21].
A strength of the study is its long follow-up interval of
10 years overall (4,796 person years for cardiovascular
disease and 5,262 person years for dementia) and that, in
addition to relations of Hcy to disease development, it
includes main determinants of Hcy levels. The evaluation
of these relations was enhanced by the access to data on
known relevant confounders. Another strength of the study
is the reliability of the ﬁles of the Swedish National Board
of Health and Welfare in which personal identiﬁcation
numbers are linked to in-hospital diagnoses (www.social
styrelsen.se) and, furthermore, that the information
obtained from these ﬁles was veriﬁed or supplemented by
information from the local hospital ﬁles and by the par-
ticipants themselves.
Regarding determinants of Hcy levels in circulation, the
GLM analysis showed a positive relation of S-Hcy to age,
male gender, MTHFR 677 TT genotype and atrophic
gastritis (both as determined morphologically and func-
tionally with PGI/PGII). Not unexpectedly, there was a
negative relation of S-Hcy to renal function, S-vitamin
B12, and S-folate. These ﬁndings are in accord with those
in other studies [2, 16, 17, 27–31], although no single
study evaluated all these parameters. We found no sig-
niﬁcant association between the MTHFR 677 TT genotype
and Hcy levels in the univariate analysis. This is not in
agreement with a previous study showing an association
with mild hyperhomocysteinemia [1]. However, recent
studies have shown a reduced effect of the MTHFR
677 TT genotype in populations with high folate intake
[32, 33]. In the GLM analysis in the present study, this
SNP had a signiﬁcant impact on Hcy levels. The appear-
ance of this signiﬁcance may be explained by the inclusion
of S-folate in the model.
Inclusion in the GLM analysis of H. pylori-associated
chronic gastritis without atrophy of the corpus mucosa did
not show any signiﬁcant relation to S-Hcy. This is in
agreement with the ﬁnding of others, namely that H. pylori
per se has no signiﬁcant impact on Hcy levels [34, 35].
There was no signiﬁcant relation of S-Hcy to the
occurrence of atrophy of the duodenal mucosa, DM, or
hypothyreosis in the GLM analysis. Others have found
increased S-Hcy levels in these diseases [5, 6, 29]. Since
the number of cases in these groups in the present study
was small, we do not draw any conclusions regarding their
impact on Hcy levels.
When using dichotomized values of S-Hcy with a cut-
off level of 14.5 lmol/l we found a positive correlation
between S-Hcy and the incidence of cardiovascular dis-
eases; in fact, the risk was doubled (OR 2.05 [1.14–3.70]).
With S-Hcy as continuous variable the relation was
weaker (OR 1.06 [1.00–1.12]). Exchanging S-Hcy for its
explanatory variables, atrophic gastritis, MTHFR 677 TT
genotype and elevated cystatin C taken together as an
independent variable in the analysis yielded a weak asso-
ciation, if any (OR 1.70 [0.92–3.13]). Since there are other
Table 5 Associations of S-Hcy levels with risk of cardiovascular
diseases grouped together (A) and dementia subgroups considered
together (B) as the dependent variable
Cut-off level for S-Hcy Odds ratio [95% conﬁdence interval]
AB
14.0 lmol/l 1.81 [1.01–3.23] 1.50 [0.50–4.46]
14.5 lmol/l 2.05 [1.14–3.70] 1.92 [0.64–5.79]
15.0 lmol/l 1.74 [0.96–3.16] 1.90 [0.63–5.68]
None (S-Hcy continuous) 1.06 [1.00–1.12] 1.09 [0.99–1.20]
Results are from logistic regression analysis adjusting for gender, age
at baseline (years), follow-up interval (months), body mass index
(kg/m
2), current smoking (yes/no), alcohol use (weekly use yes/no),
use of NSAID (weekly use yes/no), P-total cholesterol (mmol/l) and
P-triglycerides (mmol/l)
356 Dig Dis Sci (2010) 55:351–358
123causes of variations in Hcy levels than those studied here,
this lack of an association is not unexpected.
Considering the relation of Hcy to cardiovascular dis-
eases, our results are in accordance with ﬁndings in other
prospective studies, although the cut-off levels for Hcy
concentrations used vary between the studies [36–41]. In
one of these studies [36], which included 229 cases and
1,126 controls (all men, mean follow-up time 8.7 years),
there was a continuous dose-response relationship with a
41% (20%–65%) increased risk of death from ischemic
heart disease for each 5-lmol/l increase in the S-Hcy level.
In an other study [37] of 122 cases and 478 controls, the
relative risk of ischemic heart disease hospital discharges
and deaths resulting from a 4 lmol/l increase in S-Hcy was
1.32 (1.05–1.65). Whincup et al. [41], who followed a
population for 12.8 years (386 cases and 454 controls, men
aged 40–59 years at entry), found that a 47% increase in
S-Hcy was associated with a slight increase in the OR for
myocardial infarction of 1.15 (1.00–1.32). For values of
S-Hcy higher than 16.5 lmol/l, the OR for myocardial
infarction was 1.77 (1.28–2.42). As shown in the compre-
hensive meta-analysis conducted by the Homocysteine
Studies Collaboration, there are also prospective studies
that show no correlation of Hcy levels to cardiovascular
diseases [40]. This was also the case in the study by Fallon
et al. [42], which included 312 men with coronary heart
disease and 1,248 matched controls.
Althoughaccordingtotheresultsofunivariateanalysisin
the present study, S-Hcy levels seemed to be elevated in
subgroups with dementia, including dementia overall as
dependentvariableinthelogisticregressionanalysisyielded
no signiﬁcant association to Hcy levels. In a prospective
studyof1,092participants(667womenand425men)witha
median follow-up interval of 8 years, Seshadri et al. [11]
found that increased P-Hcy is an independent risk factor for
dementia and Alzheimer’s disease. The relative risk of
dementia was 1.4 (1.1–1.9) for each increase of one SD in
logarithmically transformed Hcy values. The corresponding
ﬁgure for Alzheimer’s disease was 1.8 (1.3–2.5). In an
Italian dementia-free cohort of 816 participants, Ravaglia
et al. [43] related baseline P-Hcy to incident dementia,
including Alzheimer’s disease, during a mean follow-up
interval of 4 years. They concluded that increased Hcy and
low folate concentrations are independent risk factors.
Hyperhomocysteinemia was considered to be present with a
P-Hcy higher than 15.0 lmol/l. With this cut-off level the
hazard ratio for dementia was 2.08.
To summarize, in this population-based cohort Hcy
concentrations in circulation were dependent on gender,
age, the levels of vitamin B12 and folate, as well as on
renal function, the occurrence of atrophic gastritis and the
MTHFR 677 TT genotype. There was a positive relation of
Hcy levels to incident cardiovascular diseases.
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